Signore A, Procaccini E, Chianelli M, Salerno G, Iozzo P, Annovazzi A, Leonetti F, Tamburrano G, Ronga G
Special Service of Nuclear Medicine, II Medical Clinic, University La Sapienza, Rome, Italy.
Q J Nucl Med. 1995 Dec;39(4 Suppl 1):111-2.
We evaluated the sensitivity of 111In-Octreotide scintigraphy in the diagnosis of pancreatic insulinoma in a selected number of patients. In addition, we compared the results of scintigraphy with those of other conventional diagnostic techniques. Seven patients with surgically confirmed insulinoma (< 1.5 cm in diameter) of the pancreas were studied. Before surgery, patients underwent arteriography with Ca-gluconate, CT scan, and 111In-Octreotide scintigraphy. 111In-Octreotide scintigraphy showed a higher diagnostic specificity (85%) than selective arteriography (83%) or CT scan (57%). We conclude that 111In-Octreotide scintigraphy should always be performed before surgery in cases of pancreatic insulinoma and that a SPECT acquisition should be performed both 6 and 24 hours post-injection in order to increase the diagnostic sensitivity of the test.
我们评估了铟-111奥曲肽闪烁扫描术对特定数量患者胰腺胰岛素瘤的诊断敏感性。此外，我们还将闪烁扫描术的结果与其他传统诊断技术的结果进行了比较。对7例经手术证实的胰腺胰岛素瘤（直径<1.5 cm）患者进行了研究。手术前，患者接受了葡萄糖酸钙动脉造影、CT扫描和铟-111奥曲肽闪烁扫描术。铟-111奥曲肽闪烁扫描术显示出比选择性动脉造影（83%）或CT扫描（57%）更高的诊断特异性（85%）。我们得出结论，对于胰腺胰岛素瘤患者，术前应始终进行铟-111奥曲肽闪烁扫描术，并且为了提高检查的诊断敏感性，应在注射后6小时和24小时进行SPECT采集。
